Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on immunology-based therapeutics targeting the CD40 Ligand (CD40L) pathway. The company's primary development program is tegoprubart, an IgG1 monoclonal antibody designed to modulate immune responses by inhibiting CD40L signaling. This mechanism is being evaluated for two main therapeutic applications: prevention of allograft rejection following kidney transplantation and treatment of amyotrophic lateral sclerosis (ALS). The company is also exploring the compound's potential in xenotransplantation, an emerging area addressing severe organ shortage constraints.

Eledon maintains a collaboration agreement with eGenesis, Inc., a regenerative medicine company focused on xenotransplantation solutions, which provides a partnership avenue for development in that indication. The company's earlier pipeline activities reflected this focus, though tegoprubart remains the lead clinical asset. Founded in 2011 as Novus Therapeutics, the company underwent a corporate restructuring and name change to Eledon Pharmaceuticals in January 2021 to reflect its shifted strategic focus toward immunology and transplantation.

The company operates with a lean structure of 31 full-time employees and is headquartered in Irvine, California. As a clinical-stage entity without marketed products, Eledon generates no product revenues and operates through research and development funding, including institutional capital and potential partnership support.